Announcement

Collapse
No announcement yet.

Masitinib Slows Disability Progression in PPMS and Non-active SPMS, Phase 2/3 Trial

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

    Masitinib Slows Disability Progression in PPMS and Non-active SPMS, Phase 2/3 Trial

    AB Science‘s masitinib significantly slowed disability progression in people with primary progressive multiple sclerosis (PPMS) and non-active secondary progressive MS (SPMS) at a lower dose of 4.5 mg/kg a day, top-line results from a Phase 2b/3 clinical trial show.

    Masitinib, formerly known as AB1010, is an oral therapy that inhibits the activity of cells in the innate immune system, specifically mast cells, microglia, and macrophages. In doing so, the therapy is expected to limit the inflammatory processes that cause damage to the nervous system in MS.

    It may also have applications in other conditions, including other neurological diseases and certain cancers.

    “People with primary progressive (PPMS) and non-active secondary progressive (nSPMS) forms of multiple sclerosis account for half of all MS patients,” Patrick Vermersch, PhD, a professor at University of Lille in France and a trial investigator, said in an AB Science press release.

    PPMS is estimated to affect about 15% of all MS patients, while non-active SPMS affects about 30% to 35%.

    “While numerous treatments based on targeting of B-cells and T-cells of the adaptive immune system are available for patients with relapsing forms of MS, these strategies have failed or had inconclusive results in PPMS and nSPMS. Consequently, there remains a very high medical need for people” with progressive MS forms, Vermersch added.

    https://multiplesclerosisnewstoday.c...ple-sclerosis/
    PPMS for 22 years (dx 1998)
    ~ Worrying will not take away tomorrow's troubles ~ But it will take away today's peace. ~

    #2
    I didn't realize that we have 2 immune systems!

    "Masitinib, formerly known as AB1010, is an oral therapy that inhibits the activity of cells in the innate immune system, specifically mast cells, microglia, and macrophages. In doing so, the therapy is expected to limit the inflammatory processes that cause damage to the nervous system in MS."

    "While numerous treatments based on targeting of B-cells and T-cells of the adaptive immune system are available for patients with relapsing forms of MS, these strategies have failed or had inconclusive results in PPMS and in SPMS."

    Maybe this oral therapy will show, after Phase III clinical trial, that it does significantly slow progression in those of us with PPMS and SPMS.

    Take Care
    PPMS for 22 years (dx 1998)
    ~ Worrying will not take away tomorrow's troubles ~ But it will take away today's peace. ~

    Comment


      #3
      Originally posted by KoKo View Post
      I didn't realize that we have 2 immune systems!

      "Masitinib, formerly known as AB1010, is an oral therapy that inhibits the activity of cells in the innate immune system, specifically mast cells, microglia, and macrophages. In doing so, the therapy is expected to limit the inflammatory processes that cause damage to the nervous system in MS."

      "While numerous treatments based on targeting of B-cells and T-cells of the adaptive immune system are available for patients with relapsing forms of MS, these strategies have failed or had inconclusive results in PPMS and in SPMS."

      Maybe this oral therapy will show, after Phase III clinical trial, that it does significantly slow progression in those of us with PPMS and SPMS.

      Take Care
      Interesting!

      Fingers crossed this will prove to be a good option for us! Like that it's also an oral therapy.
      Kimba

      “When you change the way you look at things, the things you look at change.” ― Max Planck

      Comment

      Working...
      X